VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
leukocyte therapy
Preclinical
Biologic
W
Wake Forest University Health Sciences
1
Indications
1
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Unresectable Cancer
Withdrawn
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Unresectable Cancer
Preclinical
Withdrawn
Clinical
Trials by Indication
[1]
Unresectable Cancer
1 trial
Donor White Blood Cell Infusion in Treating Patients With Metastatic or Unresectable Cancer
Withdrawn
·
W
Wake Forest University Health Sciences
·
N/A
·
NCT00607802
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for leukocyte therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
leukocyte therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for leukocyte therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Wake Forest University Health Sciences company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Biologic
[2]
Highest Phase
Preclinical
[1]
Company
W
Wake Forest University Health Sciences
Related News